Patient characteristics from a medical cannabis provider

Bo Angela Wan, MPhil, Alexia Blake, MSc, Stephanie Chan, BSc(C), Amiti Wolt, BA, Pearl Zaki, BSc(C), Liying Zhang, PhD, Marissa Slaven, MD, Erynn Shaw, MD, Carlo DeAngelis, PharmD, Henry Lam, MLS, Vithusha Ganesh, BSc(C), Leila Malek, BSc(Hons), Edward Chow, MBBS, and Shannon O’Hearn, MSc Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada MedReleaf, Markham, Ontario, Canada Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada

[1]  Xia Zhang,et al.  Endocannabinoid system: Role in depression, reward and pain control (Review) , 2016, Molecular medicine reports.

[2]  Matthew D. DiDonato,et al.  Medical Cannabis in Arizona: Patient Characteristics, Perceptions, and Impressions of Medical Cannabis Legalization , 2015, Journal of psychoactive drugs.

[3]  Alan J. Thompson,et al.  Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity , 2014, Neurology.

[4]  Robert Kay,et al.  Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. , 2013, The International journal on drug policy.

[5]  C. Reinarman,et al.  Who Are Medical Marijuana Patients? Population Characteristics from Nine California Assessment Clinics , 2011, Journal of psychoactive drugs.

[6]  George A Fraser,et al.  The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) , 2009, CNS neuroscience & therapeutics.

[7]  Timothy S. Carey,et al.  Accuracy of the Pain Numeric Rating Scale as a Screening Test in Primary Care , 2007, Journal of General Internal Medicine.

[8]  J. Manzanares,et al.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. , 2006, Current neuropharmacology.

[9]  M. Amar.  Cannabinoids in medicine: A review of their therapeutic potential. , 2006 .

[10]  M. Elsohly,et al.  Chemical constituents of marijuana: the complex mixture of natural cannabinoids. , 2005, Life sciences.

[11]  F. Grotenhermen.  The Cannabinoid System-A Brief Review , 2004 .

[12]  R. Birch,et al.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial , 2004, Pain.

[13]  H. Adams,et al.  The medicinal use of cannabis in the UK: results of a nationwide survey , 2004, International journal of clinical practice.

[14]  F. Grotenhermen.  Clinical Pharmacodynamics of Cannabinoids , 2004 .

[15]  C. Burckhardt,et al.  The Quality of Life Scale (QOLS): Reliability, Validity, and Utilization , 2003, Health and quality of life outcomes.

[16]  J. Farrar,et al.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale , 2001, PAIN.

[17]  D. Spiegelhalter,et al.  Quality of life measures in health care. II: Design, analysis, and interpretation. , 1992, BMJ.

[18]  A. Hazekamp,et al.  Review on clinical studies with cannabis and cannabinoids 2005-2009 , 2010 .